88559-56-2

Upstream product

• 163226-43-5 1-O-tert-butyldimethysilyl-2,3-O-isopropylidene-5-O-tritylribitol-4-ulose 
• 532-20-7 D-Ribose 
• 681854-00-2 C₂₈H₂₈O₄ 
• 50-69-1 D-ribose 
• 106886-17-3 2,3-O-isopropylidene-5-O-triphenylmethyl-D-ribono-1,4-lactone 
• 106886-19-5 {2-[(4R,5R)-5-((R)-1-Hydroxy-2-trityloxy-ethyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-2-oxo-ethyl}-phosphonic acid diethyl ester 
• 106886-18-4 ((3aR,4R,6R,6aR)-4-Hydroxy-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl)-phosphonic acid diethyl ester 
• 76-83-5 trityl chloride 
• 30725-00-9 2,3-O-isopropylidene-D-ribonic-γ-lactone 
• 88559-50-6 (4R,5S)-5-[(R)-1-(tert-Butyl-dimethyl-silanyloxy)-2-trityloxy-ethyl]-2,2-dimethyl-[1,3]dioxolane-4-carbaldehyde 
• 88559-53-9 (2-{(4R,5S)-5-[(R)-1-(tert-Butyl-dimethyl-silanyloxy)-2-trityloxy-ethyl]-2,2-dimethyl-[1,3]dioxolan-4-yl}-2-oxo-ethyl)-phosphonic acid dimethyl ester 
• 88559-52-8 (2-{(4S,5S)-5-[(R)-1-(tert-Butyl-dimethyl-silanyloxy)-2-trityloxy-ethyl]-2,2-dimethyl-[1,3]dioxolan-4-yl}-2-hydroxy-ethyl)-phosphonic acid dimethyl ester 
• 88559-48-2 2,2-Dimethyl-propionic acid (4S,5S)-5-[(R)-1-(tert-butyl-dimethyl-silanyloxy)-2-trityloxy-ethyl]-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 
• 88559-54-0 {2-[(4R,5R)-5-((R)-1-Hydroxy-2-trityloxy-ethyl)-2,2-dimethyl-[1,3]dioxolan-4-yl]-2-oxo-ethyl}-phosphonic acid dimethyl ester 

Downstream Products

• 805245-38-9 (3aR,6aR)-5-iodo-2,2-dimethyl-6-((trityloxy)methyl)-3aH-cyclopenta[d][1,3]dioxol-4(6aH)-one 
• 865838-14-8 (3R,4S,6aR)-3-benzoyl-1-(5-fluoro-2,2-dimethyl-6-trityloxymethyl-4,6a-dihydro-3aH-cyclopenta[1,3]dioxol-4-yl)-1H-pyrimidine-2,4-dione 
• 1373332-60-5 C₂₉H₄₁FN₂O₇SSi₂ 
• 865838-26-2 RX-3117 
• 491578-02-0 (3aS,4R,6aR)-6-(benzyloxymethyl)-5-fluoro-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 491578-01-9 ((3aR,4R,6aR)-6-(benzyloxymethyl)-5-iodo-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)(tert-butyl)diphenylsilane 

Relevant academic research and scientific papers

POLYMORPHIC COMPOUNDS AND USES THEREOF

The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

Tumor immunity compound and application thereof

Disclosed are a tumor immunity compound and an application thereof. The invention discloses a compound as shown in the formula (I), optical isomers thereof, and pharmaceutically acceptable salts thereof, and an application of the compound as an STING agonist.

Syntheses of cyclopentyl nucleoside (?)-neplanocin A through tetrazole-fragmentation from cyanophosphates

We recently reported a novel synthetic method for five-membered unsaturated cyclic compounds from ketones involving cyanophosphates (CPs) under neutral conditions, in which alkylidene carbenes generated through tetrazole-fragmentation undergo [1,5]-C–H in

Nucleoside derivatives and therapeutic uses therof

The present invention relates to nucleoside derivatives represented by general formulas I and II, their synthetic methods and their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperprolifera

Stereoselective synthesis of 3-hydroxymethyl-D-cyclopentenone, the versatile intermediate for the synthesis of carbocyclic nucleosides

The preparative and stereoselective synthesis (45-50% overall yields, >50 g scale) of the key carbasugars 7a-d was achieved from D-ribose via stereoselective Grignard reaction and oxidative rearrangement as key reactions. Copyright Taylor & Francis, Inc.

An improved approach to chiral cyclopentenone building blocks. Total synthesis of pentenomycin I and neplanocin A

An improved approach to enantiomerically pure hydroxylated cyclopentenones is reported here, which involves intramolecular nitrone cycloaddition of sugar-derived chiral pent-4-enals and hex-5-en-ones-2 followed by N-O bond cleavage, quaternization of the amine thus produced, and finally oxidative elimination of the amino group. Synthesis of pentenomycin I and neplanocin A is described following this methodology.

Preparative and Stereoselective Synthesis of the Versatile Intermediate for Carbocyclic Nucleosides: Effects of the Bulky Protecting Groups to Enforce Facial Selectivity

The preparative and stereoselective synthesis (45-50% overall yields) of the target compound 17 has been accomplished from D-ribose. The bulky protecting groups such as TBDPS and Trityl enforced the facial selectivity during Grignard reaction to give the

Synthesis of (-)-Neplanocin A via C-H Insertion of Alkylidenecarbene

(-)-Neplanocin A, a naturally occurring carbocyclic nucleoside was synthesized via C-H insertion reaction of the alkylidenecarbene, which was generated by the reaction of lithiotrimethylsilyldiazomethane and the ketone derived from D-ribose.

EINFACHE, REGIOSPECIFISCHE SYNTHESE VON CYCLOALKENONEN AUS LACTONEN

The reaction of lithiumalkylphosphonates with γ- or δ-lactones followed by oxidation leads to 2,5- or 2,6-dioxophosphonates, which can be cyclized to cyclopentanones or cyclohexanones, respectively, constituting an easy, regiospecific route to cycloalkanones from lactones.

A synthetic approach towards neplanocin A: Preparation of the optically active cyclopentene moiety from D-ribose

D (-)-ribose has been converted to the chiral 2-cyclopenten-1-one derivative 13 which has the correct stereochemistry and appropriate functionalities for the construction of neplanocin A.